BR 116
Alternative Names: BR-116Latest Information Update: 01 Jul 2025
At a glance
- Originator BioRay Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 25 Apr 2025 Preclinical trials in Gastrointestinal cancer in China (Parenteral), prior to April 2025
- 25 Apr 2025 Adverse events and pharmacodynamics data from preclinical trial in Gastrointestinal cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 BioRay Biopharmaceutical announces intention to submit IND to Regulatory authorities in 2025